Improvement of endothelial function by pitavastatin: a meta-analysis

References

• Reiner Z. Statins in the primary prevention of cardiovascular disease. Nature Rev Cardiol. 2013;10(8):453–464.
   PubMed Web of Science ®Google Scholar
• Graham I, Cooney MT, Bradley D, et al. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14(6):709–720.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Management of patients with familial hypercholesterolaemia. Nature Rev Cardiol. 2015;12(10):565–575.
   PubMed Web of Science ®Google Scholar
• Collaboration EASFHS, Vallejo-Vaz AJ, Akram A, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial hypercholesterolaemia studies collaboration. Atherosclerosis Suppl. 2016;22:1–32.
   PubMed Web of Science ®Google Scholar
• Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis. 2015;243(1):257–259.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Progr Lipid Res. 2015;60:50–73.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Kotani K, Serban C, et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241(2):433–442.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Serban C, Mikhailidis DP, et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015;114(3):546–557.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Giua R, Pedone C, et al. Fibrate therapy and flow-mediated dilation: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016;111:163–179.
   PubMed Web of Science ®Google Scholar
• Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Scientific Reports. 2015;5:9902.
   PubMed Web of Science ®Google Scholar
• Parizadeh SM, Azarpazhooh MR, Moohebati M, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011;46(4):333–340.
   PubMed Web of Science ®Google Scholar
• Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631–639.
   PubMed Web of Science ®Google Scholar
• Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs. 2012;72(4):565–584.
   PubMed Web of Science ®Google Scholar
• Saku K, Zhang B, Noda K, et al. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circulation J. 2011;75(6):1493–1505.
   PubMed Web of Science ®Google Scholar
• Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obesity Metab. 2011;13(11):1047–1055.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Gong RR, Qiu L, et al. Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2014;34(9):599–608.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–1361.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013;23(9):799–807.
   PubMed Web of Science ®Google Scholar
• Ganjali S, Momtazi AA, Banach M, et al. HDL abnormalities in familial hypercholesterolemia: focus on biological functions. Progr Lipid Res. 2017;67:16–26.
   PubMed Web of Science ®Google Scholar
• Kishida K, Funahashi T, Shimomura I. Importance of assessing the effect of statins on the function of high- density lipoproteins on coronary plaque. Cardiovasc Hematol Disord Drug Targets. 2012;12(1):28–34.
   PubMedGoogle Scholar
• Chiba, Yokote K, Saito Y. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb. 2009;16(3):297–298.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Shimano H, Yokote K, et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11(5):817–828.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26(5):1235–1241.
   PubMed Web of Science ®Google Scholar
• Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168–175.
   PubMed Web of Science ®Google Scholar
• Li H, Horke S, Forstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 2014;237(1):208–219.
   PubMed Web of Science ®Google Scholar
• Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb. 2013;20(1):1–8.
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Versari D, Giannarelli C, et al. Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des. 2008;14(35):3715–3722.
   PubMed Web of Science ®Google Scholar
• Bots ML, Westerink J, Rabelink TJ, et al. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J. 2005;26(4):363–368.
   PubMed Web of Science ®Google Scholar
• Pirro M, Bagaglia F, Paoletti L, et al. Hypercholesterolemia-associated endothelial progenitor cell dysfunction. Ther Adv Cardiovasc Dis. 2008;2(5):329–339.
   PubMedGoogle Scholar
• Pirro M, Schillaci G, Romagno PF, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther. 2009;14(1):14–21.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations – a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329–336.
   PubMed Web of Science ®Google Scholar
• Sahebkar A. Does PPARgamma2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol. 2013;32(4):188–198.
   PubMed Web of Science ®Google Scholar
• Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013;71(12):822–835.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463.
   PubMed Web of Science ®Google Scholar
• Nagashima H, Endo M. Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart Vessels. 2011;26(4):428–434.
   PubMed Web of Science ®Google Scholar
• Takase B, Hattori H, Tanaka Y, et al. Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia. Heart Asia. 2013;5(1):204–209.
   PubMedGoogle Scholar
• Yan HM, Zhao J, Ma DZ, et al. The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia. Expert Opin Pharmacother. 2011;12(10):1463–1471.
   PubMed Web of Science ®Google Scholar
• Yoshida O, Kondo T, Kureishi-Bando Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circulation J. 2010;74(1):195–202.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yan HM, Li Y, et al. Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia. J Zhejiang Univ Sci B. 2015;16(5):380–387.
   PubMed Web of Science ®Google Scholar
• Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136–138.
   PubMed Web of Science ®Google Scholar
• Muto E. Pitavastatin ameliorates endothelial function in diabetics. Japanese Pharmacol Therapeut. 2013;41(7):685–688.
   Google Scholar
• Wilmink HW, Twickler MB, Banga JD, et al. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. Cardiovasc Res. 2001;50(3):577–582.
   PubMed Web of Science ®Google Scholar
• Parhofer KG, Barrett PH, Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 2000;85(11):4224–4230.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis. 2013;227(2):367–372.
   PubMed Web of Science ®Google Scholar
• Amudha K, Choy AM, Mustafa MR, et al. Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus. Cardiovasc Therapeut. 2008 Winter;26(4):253–261.
   PubMed Web of Science ®Google Scholar
• Brili S, Tousoulis D, Antonopoulos AS, et al. Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. Heart. 2012;98(4):325–329.
   PubMed Web of Science ®Google Scholar
• Taneva E, Borucki K, Wiens L, et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol. 2006;97(7):1002–1006.
   PubMed Web of Science ®Google Scholar
• Koh KK, Oh PC, Sakuma I, et al. Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Int J Cardiol. 2016;223:488–493.
   PubMed Web of Science ®Google Scholar
• Egede R, Jensen LO, Hansen HS, et al. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients. Int J Cardiol. 2012;158(3):376–379.
   PubMed Web of Science ®Google Scholar
• Kishimoto N, Hayashi T, Sakuma I, et al. A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis. Int J Cardiol. 2010;145(1):21–26.
   PubMed Web of Science ®Google Scholar
• Ferreira WP, Bertolami MC, Santos SN, et al. One-month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescents. Pediatric Cardiol. 2007;28(1):8–13.
   PubMed Web of Science ®Google Scholar
• Miyaki K, Matsubara A, Nishiwaki A, et al. Pitavastatin attenuates leukocyte-endothelial interactions induced by ischemia-reperfusion injury in the rat retina. Curr Eye Res. 2009;34(1):10–17.
   PubMed Web of Science ®Google Scholar
• Takagi H, Yamamoto H, Iwata K, et al. Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: a meta-analysis and meta-regression of randomized controlled trials. Int J Cardiol. 2012;158(2):285–289.
   PubMed Web of Science ®Google Scholar
• Tsubouchi H, Inoguchi T, Sonta T, et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radical Biol Med. 2005;39(4):444–452.
   PubMed Web of Science ®Google Scholar
• Shinozaki K, Nishio Y, Ayajiki K, et al. Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production. J Cardiovasc Pharmacol. 2007;49(3):122–130.
   PubMed Web of Science ®Google Scholar
• Poolsup N, Suksomboon N, Wongyaowarat K, et al. Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. J Clin Pharm Ther. 2012;37(2):166–172.
   PubMed Web of Science ®Google Scholar
• Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29(11):2365–2373.
   PubMed Web of Science ®Google Scholar
• Lu Y, Cheng Z, Zhao Y, et al. Efficacy and safety of long-term treatment with statins for coronary heart disease: a Bayesian network meta-analysis. Atherosclerosis. 2016;254:215–227.
   PubMed Web of Science ®Google Scholar
• Ose L. Pitavastatin: finding its place in therapy. Therapeut Adv Chronic Dis. 2011;2(2):101–117.
   PubMedGoogle Scholar
• Simic I, Reiner Z. Adverse effects of statins – myths and reality. Curr Pharm Des. 2015;21(9):1220–1226.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Rizzo M, Mikhailidis DP, et al. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism: Clinc Exp. 2015;64(4):471–475.
   PubMed Web of Science ®Google Scholar
• Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des. 2013;19(27):4904–4912.
   PubMed Web of Science ®Google Scholar